According to Benzinga, equity research analysts at JPMorgan Chase & Co. lowered their price objective for Sotera Health (NYSE: SHC) in a research note that was handed out to clients and investors on Thursday. The new price objective is $6.00, down from $9.00. Based on their analysis, the brokerage company has placed the stock in the “underweight” category. Compared to the most recent price at which the stock has been trading, the price target established by JPMorgan Chase & Co. indicates that there is a possibility of a decline of 4.00% from the current price.
Recently, we have seen an increase in other equity analysts who have mentioned the company in their conversations. Goldman Sachs Group decreased their price objective for Sotera Health from $23.00 to $9.00. It downgraded the company from a “buy” rating to a “neutral” rating in a report published on Tuesday, September 20th. In addition, they moved Sotera Health from a “buy” recommendation to a “neutral” rating in their company assessment. TheStreet lowered its rating for Sotera Health from “c-” to “d” in a research note published on September 19th. This change was made in response to the overall performance of the company. In a research note made available on Thursday, the Royal Bank of Canada disclosed that it had lowered its “outperform” rating on shares of Sotera Health and its price objective on those shares, which had previously been set at $25.00. The new price objective is $8.00. Finally, in a report distributed on Wednesday, October 5th, Citigroup lowered their price target for Sotera Health from $25.00 to $9.00 and changed their recommendation for the company from “buy” to “neutral.”
Last but not least, in a research report released on Thursday, October 6th, Barclays decreased their price objective for Sotera Health from $22.00 to $8.00 and rated the company as “equal weight.” Three financial analysts have recommended that investors buy the company’s stock, five have suggested that investors maintain their current holdings, and one has suggested that investors sell the stock. According to information from Bloomberg.com, the stock is currently given an average “Hold” recommendation, and market watchers forecast that the price will rise to $16.22 in the not-too-distant future.
This past Thursday saw a decrease of $0.05 in the price of a share of SHC stock, bringing the total price to $6.25. There were 89,283 shares traded in the company’s stock, with an average volume of 1,785,941 shares trading hands. The 52-week low for Sotera Health’s share price was $6.27, while the 52-week high for the stock was $27.38. The company’s market capitalization is currently sitting at $1.77 billion, its PE ratio is 13.96, and its beta stands at 1.28. The moving average price of the share of the stock calculated over the past 200 days is $16.64, and the moving average price calculated over the last 50 days is $10.28. The quick ratio is 2.53, the current ratio is 281, and the debt-to-equity ratio is 2.83. All of these numbers are in ratio form. Therefore, these numbers are all presented in the form of a ratio.
The most recent earnings report for Sotera Health, published on August 4th and can be found under the ticker symbol “NYSE: SHC,” can be found here. In the end, the company reported $0.25 per share earnings for the period, which is $0.02 more than the consensus estimate of $0.23 per share. The return on equity for Sotera Health was calculated to be 41.00%, and the net margin for the company came in at 12.82%. The sales for the company for the quarter came in significantly higher than the predictions of $256.30 million that the analysts had made, coming in instead at $266.40 million. As a result, many reported $0.25 per share earnings for the period, which is $0.02 more than the consensus estimate of $0.23 per share. The return on equity for Sotera Health was calculated to be 41.00%, and the net margin for the company came in at 12.82%. The sales for the company for the quarter came in significantly higher than the predictions of $256.30 million that the analysts had made, coming in instead at $266.40 million.
Compared to the same period in the previous year, the third quarter saw a revenue increase of 5.8% for the company. The company posted earnings of $0.25 per share for the same period the year before when compared to the current year. In the current fiscal year, Sotera Health is expected to generate $0.91 per share, according to forecasts provided by professionals specializing in equity research.
Recent months have seen several institutional investors make adjustments to the way they are currently invested in the company’s stock:
The Teacher Retirement System of Texas increased the percentage of Sotera Health stock owned by an impressive 84.8% over the third quarter. The Teacher Retirement System of Texas now has 29,732 shares of the company’s stock, which can be valued at $203,000 thanks to purchasing an additional 13,641 shares during the period in question.
Barclays PLC increased the amount of Sotera Health stock owned by 50.5% during the third quarter of the fiscal year. Barclays PLC increased its holdings in the company during the most recent quarter by 7,773, bringing the total number of shares it owns to 23,171. The value of these shares due to the purchase is $158,000.
Bronte Capital Management Pty Ltd. increased the proportion of Sotera Health stock owned by 19.1 percent during the third quarter.
After acquiring an additional 132,458 shares during the most recent quarter, Bronte Capital Management Pty Ltd. now holds 824,197 shares of the company’s stock in its portfolio. Their shareholdings in the company are currently worth a total of $5,621,000 in market value. Finally, during the third quarter, SG Americas Securities LLC achieved a 92.4% increase in the amount of Sotera Health stock that it owned, thanks to the company’s successful investment strategies. After purchasing an additional 17,609 shares over the preceding three months, SG Americas Securities LLC now owns 36,661 shares. Based on the market price of a share, the company has a total value of $250,000.
Last but not least, Strs Ohio increased the percentage of Sotera Health stock owned by 29.0% during the third quarter. This certainly should not be considered the least important item. Strs Ohio now has 56,370 shares of the company’s stock after purchasing an additional 12,664 shares during the most recent quarter. As a result, the value of Strs Ohio’s complete holdings in the corporation’s stock comes to $384,000. Now, hedge funds and other institutional investors own 88.38% of the company’s common stock.
The Sotera Health Company provides a variety of services all over the world, such as in the United States of America, Canada, Europe, and other parts of the world. These services include sterilization, laboratory testing, and consultation. In addition to providing sterilization services for the medical device and biopharmaceutical industries, such as gamma and electron beam irradiation and EO processing, Nelson Labs also offers testing in microbiology and analytical chemistry well as consulting services. EO processing is an additional service that can be obtained from Nelson Labs.
Source: news.google.com
